A new study may pave the way toward more personalized treatments for patients with high-risk bladder cancer, according to a study published in European Urology.

Detalimogene voraplasmid lead to numerous durable complete responses with favorable safety ...

A new implantable device which aims to maximise the effectiveness of light-sensitive drugs could improve outcomes for bladder ...

Pelvic floor dysfunction can contribute to chronic urinary tract infections. Relaxing the pelvic floor muscles in physical ...

You laugh at your best friend's joke—and feel a little leak. You sneeze in the grocery store and freeze. You skip the ...

A new survey undertaken by the Harris Poll for Johnson & Johnson has shown how standard forms of surgery and treatment for ...

The Scottish Medicines Consortium has approved a new first-line combination therapy for restricted use in adults with unresectable or metastatic urothelial cancer.

But all that changed when she started experiencing debilitating bladder spasms and urinary incontinence, and later daily ...

AstraZeneca’s first foray with PD-L1 inhibitor Imfinzi as a treatment for bladder cancer was a flop. | Following an FDA ...

ImmunityBio, Inc. receives a Strong Buy rating, driven by ANKTIVA's compelling clinical data and major regulatory catalysts ...

Merck (MRK) shares rose nearly 5% in early trade on Friday after the company said a European medicines committee issued a ...